---
title: "Tumor-bed Boost After BCS for Young Women With Margin-negative IDC: Does a 10 Gy Boost Improve Out"
id: "pubmed-42674682"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42674682"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42674682/"
doi: "10.21873/anticanres.18367"
published_at: "2026-09-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Tumor-bed Boost After BCS for Young Women With Margin-negative IDC: Does a 10 Gy Boost Improve Out
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42674682
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42674682/)
- **DOI:** [10.21873/anticanres.18367](https://doi.org/10.21873%2Fanticanres.18367)
- **Published At:** 2026-09-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This single-center retrospective study assessed whether adding a **10 Gy tumor-bed boost** to whole-breast irradiation (WBI) improves local control in women ≤50 years with **invasive ductal carcinoma (IDC)** and widely negative surgical margins (>5 mm) after **breast-conserving surgery (BCS)**. - The cohort included 318 patients treated at Tohoku University Hospital between 2008 and 2022; 110 received boost irradiation (patients treated from 2016 onward) and 208 did not (treated before 2016). - Luminal subtype predominated in both groups; triple-negative disease was uncommon. No other subtype breakdown or systemic therapy details were reported in the abstract. - Median follow-up was 95.5 months. The 7-year **ipsilateral breast tumor recurrence (IBTR)** rates were 1.2% in the boost group and 0% in the non-boost group; the difference was not statistically significant (log-rank p = 0.859). - Seven-year overall survival (OS) was 96.6% with boost versus 97.9% without boost; this difference was also not statistically significant (log-rank p = 0.616). - The authors conclude that adding a 10 Gy tumor-bed boost did not significantly improve IBTR or OS in this carefully selected low-risk population, supporting a **risk-adapted** postoperative radiotherapy approach and suggesting routine boost irradiation may not be necessary for such patients. - Study design, inclusion criteria (age ≤50, IDC, margin >5 mm), boost dose (10 Gy), follow-up duration, sample sizes, and primary endpoints (IBTR and OS) were reported; other details such as toxicity, cosmetic outcomes, systemic therapy regimens, and multivariable analyses were not reported in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42674682/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674682%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42674682/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42674682/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42674682/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42674682/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42674682/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674682%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674682%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42674682/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674682/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674682/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42674682/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42674682/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42674682/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42674682/#abstract) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42674682/#mesh-terms) Title & authors Abstract MeSH terms Anticancer Res Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Res%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Res%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) . 2026 Sep;46(9):5229-5238. doi: 10.21873/anticanres.18367. # Is Tumor Bed Boost Necessary in Young Patients With Margin-negative Invasive Ductal Carcinoma in the Modern Radiotherapy Era? [Yimo Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Y&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#full-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."), [Keiichi Jingu](https://pubmed.ncbi.nlm.nih.gov/?term=Jingu+K&cauthor_id=42674682)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#full-view-affiliation-2 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan Keiichi.jingu.e8@tohoku.ac.jp."), [Noriyoshi Takahashi](https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi+N&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#full-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."), [Takaya Yamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+T&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#full-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."), [Rei Umezawa](https://pubmed.ncbi.nlm.nih.gov/?term=Umezawa+R&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#full-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.") Affiliations Expand ### Affiliations * 1 Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. * 2 Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan Keiichi.jingu.e8@tohoku.ac.jp. * PMID: **42674682** * DOI: [ 10.21873/anticanres.18367 ](https://doi.org/10.21873/anticanres.18367) Item in Clipboard # Is Tumor Bed Boost Necessary in Young Patients With Margin-negative Invasive Ductal Carcinoma in the Modern Radiotherapy Era? Yimo Wang et al. Anticancer Res. 2026 Sep. Show details Display options Display options Format Abstract PubMed PMID Anticancer Res Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Res%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Res%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) . 2026 Sep;46(9):5229-5238. doi: 10.21873/anticanres.18367. ### Authors [Yimo Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Y&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#short-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."), [Keiichi Jingu](https://pubmed.ncbi.nlm.nih.gov/?term=Jingu+K&cauthor_id=42674682)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#short-view-affiliation-2 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan Keiichi.jingu.e8@tohoku.ac.jp."), [Noriyoshi Takahashi](https://pubmed.ncbi.nlm.nih.gov/?term=Takahashi+N&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#short-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."), [Takaya Yamamoto](https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto+T&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#short-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan."), [Rei Umezawa](https://pubmed.ncbi.nlm.nih.gov/?term=Umezawa+R&cauthor_id=42674682)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42674682/#short-view-affiliation-1 "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.") ### Affiliations * 1 Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. * 2 Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan Keiichi.jingu.e8@tohoku.ac.jp. * PMID: **42674682** * DOI: [ 10.21873/anticanres.18367 ](https://doi.org/10.21873/anticanres.18367) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Background/aim:** To evaluate whether tumor-bed boost irradiation improves local control outcomes in women aged 50 years or younger with invasive ductal carcinoma (IDC) and widely negative margins after breast-conserving surgery (BCS), and to clarify its clinical value within a modern, risk-adapted radiotherapy strategy. **Patients and methods:** This retrospective single-center study included 318 female patients aged ≤50 years with IDC and negative surgical margins (>5 mm) who underwent BCS followed by whole-breast irradiation (WBI) at Tohoku University Hospital between 2008 and 2022. Patients treated before 2016 did not receive boost irradiation, whereas those treated thereafter received a 10 Gy tumor-bed boost. Survival estimates were calculated using the Kaplan-Meier method from the first date of radiotherapy. **Results:** Among the 318 eligible patients, 110 received boost irradiation and 208 did not. Luminal disease was the predominant subtype in both groups (87/110 in the boost group and 159/208 in the non-boost group), whereas triple-negative disease was uncommon (11/110 and 18/208, respectively). After a median follow-up of 95.5 months, the 7-year ipsilateral breast tumor recurrence (IBTR) rates were 1.2% and 0% (log-rank _p_ =0.859), while the 7-year overall survival (OS) rates were 97.9% in the non-boost group and 96.6% in the boost group (log-rank _p_ =0.616), respectively. There were no significant differences in IBTR or OS between groups. **Conclusion:** In female patients aged ≤50 years with IDC and widely negative surgical margins following BCS, the addition of a 10 Gy tumor-bed boost did not demonstrate a significant improvement in IBTR or OS. These findings suggest that routine boost irradiation may not be necessary in carefully selected low-risk patients and support a risk-adapted approach to postoperative radiotherapy. **Keywords:** Breast-conserving surgery; boost radiation; invasive ductal carcinoma; surgical margin; younger patients. Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## MeSH terms * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Breast Neoplasms* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Breast Neoplasms* / radiotherapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fradiotherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Breast Neoplasms* / surgery Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Breast+Neoplasms%2Fsurgery%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Breast+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Carcinoma, Ductal, Breast* / pathology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Ductal%2C+Breast%2Fpathology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Ductal%2C+Breast) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Carcinoma, Ductal, Breast* / radiotherapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Ductal%2C+Breast%2Fradiotherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Ductal%2C+Breast) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Carcinoma, Ductal, Breast* / surgery Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Carcinoma%2C+Ductal%2C+Breast%2Fsurgery%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Carcinoma%2C+Ductal%2C+Breast) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Female Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Female%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Female) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Margins of Excision Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Margins+of+Excision%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Margins+of+Excision) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Mastectomy, Segmental Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mastectomy%2C+Segmental%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mastectomy%2C+Segmental) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Middle Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Middle+Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Middle+Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Neoplasm Recurrence, Local Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Neoplasm+Recurrence%2C+Local%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Neoplasm+Recurrence%2C+Local) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Radiotherapy, Adjuvant Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Radiotherapy%2C+Adjuvant%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Radiotherapy%2C+Adjuvant) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) * Retrospective Studies Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Retrospective+Studies%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Retrospective+Studies) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42674682/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42674682/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674682%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42674682/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674682%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42674682%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42674682/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/)
## Related Clinical Research

- [Nurses' Role in Comprehensive Endometriosis Care: Beyond Pain Management](https://medichelpline.com/clinical-feed/pubmed-42765750.md) (DOI: 10.1097/NSG.0000000000000463)
- [FDA Removes Boxed Warning for Menopausal Hormone Therapy: Key Points for Nurses](https://medichelpline.com/clinical-feed/pubmed-42765755.md) (DOI: 10.1097/NSG.0000000000000411)
- [FDA Revises Nonclinical Testing Rules to Advance Alternatives to Animal Studies](https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing.md)
- [Novo Nordisk outlines obesity and direct-to-consumer push, pledges five 'multi-blockbusters' by 20](https://medichelpline.com/clinical-feed/stat-news-1-stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to-consumer-work.md)
- [Trump Announces GENEROUS Medicaid Drug-Discount Model; 40 States Reportedly Signed So Far](https://medichelpline.com/clinical-feed/stat-news-0-stat-trump-touts-pharma-deals-to-offer-cheaper-drugs-to-state-medicaid-programs.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.